Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

HMPL-306 (ranosidenib)

NCT07912398

Hutchmed · Phase 3 · Not yet recruiting · Enrollment 210

NCT07912398

Catalyst Primary completion. 03.2032. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
HMPL-306 250 mg QDIDH-mutant grade 2 or 3 glioma (n = 210)250 mgITTplacebon/r

No efficacy figure is in this file for this study.